Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma

Previous studies have shown that mithramycin A (MIT) is a promising candidate for the treatment of pancreatic carcinoma through inhibiting transcription factor Sp1. However, systemic toxicities may limit its clinical application. Here, we report a rationally designed formulation of MIT-loaded nanopa...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xu-Jie, Li, Liang, Liu, Xiu-Jun, Li, Yi, Zhao, Chun-Yan, Wang, Rui-Qi, Zhen, Yong-Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533565/
https://www.ncbi.nlm.nih.gov/pubmed/28769562
http://dx.doi.org/10.2147/IJN.S139507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533565/
https://www.ncbi.nlm.nih.gov/pubmed/28769562
http://dx.doi.org/10.2147/IJN.S139507

Ejemplares similares